Given CMGCL's capability in upregulating PD‐L1 expression on tumor cells, CMGCL could be potentially applied as a sensitizer for αPD‐L1 immunotherapy, and generate synergistic effects via a combined therapy. The gene discussed is CD274; the disease is neoplasm.